Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis

Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis

Background: Targeted therapy with EGFR tyrosine-kinase inhibitors (TKIs) is the preferred first-line treatment for EGFR-mutated advanced non-small-cell lung cancer (NSCLC), but acquired resistance inevitably occurs in almost all responding individuals. Objectives: We aimed to comprehensively review...

Full description

Saved in:
Bibliographic Details
Main Authors: Wengang Zhang, Jian Xiong, Yujie Li, Jing Nie, Wencheng Zhao, Zhiyi Guo, Xinyue Liu, Qianqian Zhang, Xuyang Chen, Li Ye, Zhimin Chen, Hao Wang, Kandi Xu, Lishu Zhao, Yujin Liu, Lihua Huang, Yuhang Li, Yayi He
Format: Article
Language:English
Published: SAGE Publishing 2025-05-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359251338046
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/17588359251338046

Similar Items